- Home
- IAG vs ACAD Comparison
IAG vs ACAD Comparison
Compare IAG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAG
- ACAD
- Stock Information
- Founded
- IAG 1990
- ACAD 1993
- Country
- IAG Canada
- ACAD United States
- Employees
- IAG N/A
- ACAD N/A
- Industry
- IAG Precious Metals
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- IAG Basic Materials
- ACAD Health Care
- Exchange
- IAG Nasdaq
- ACAD Nasdaq
- Market Cap
- IAG 4.0B
- ACAD 3.8B
- IPO Year
- IAG 1996
- ACAD 2004
- Fundamental
- Price
- IAG $6.91
- ACAD $22.54
- Analyst Decision
- IAG Buy
- ACAD Buy
- Analyst Count
- IAG 6
- ACAD 18
- Target Price
- IAG $8.61
- ACAD $27.71
- AVG Volume (30 Days)
- IAG 13.5M
- ACAD 2.1M
- Earning Date
- IAG 08-07-2025
- ACAD 08-05-2025
- Dividend Yield
- IAG N/A
- ACAD N/A
- EPS Growth
- IAG 405.77
- ACAD N/A
- EPS
- IAG 1.42
- ACAD 1.37
- Revenue
- IAG $1,771,200,000.00
- ACAD $996,283,000.00
- Revenue This Year
- IAG $49.23
- ACAD $13.28
- Revenue Next Year
- IAG $8.82
- ACAD $11.06
- P/E Ratio
- IAG $4.89
- ACAD $16.50
- Revenue Growth
- IAG 61.05
- ACAD 22.42
- 52 Week Low
- IAG $3.44
- ACAD $13.40
- 52 Week High
- IAG $8.38
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- IAG 43.35
- ACAD 59.56
- Support Level
- IAG $6.90
- ACAD $20.87
- Resistance Level
- IAG $7.22
- ACAD $23.12
- Average True Range (ATR)
- IAG 0.26
- ACAD 0.68
- MACD
- IAG -0.04
- ACAD 0.04
- Stochastic Oscillator
- IAG 15.82
- ACAD 75.32
About IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.